# Invesco NASDAQ Biotech UCITS ETF (SBIX) **Source:** https://fundology.uk/fund/sbix · ISIN IE00BQ70R696 · Data: TradingView (LSE closes and returns, delayed), issuer documents, ONS CPIH, FCA FIRDS ## At a glance > Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise. As of 30/09/2026, SBIX (Invesco NASDAQ Biotech UCITS ETF, ISIN IE00BQ70R696) closed at £56.33 on the London Stock Exchange. Its ongoing charge is 0.40% a year (about £40 on £10,000). Over the five years to 30/09/2026 its total return was +35.2%, or +5.7% after UK CPIH inflation. ## Summary Invesco NASDAQ Biotech UCITS ETF is an exchange-traded fund (ETF) from Invesco, launched in 2014. It tracks the NASDAQ / Biotechnology. You buy and sell it through a share-dealing account or platform during stock-market hours, like a share. Its ongoing charge is 0.4% a year — about £40 a year on every £10,000 invested, taken from the fund's value rather than billed to you. Income from its investments is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you. Latest close: **£56.33** (30/09/2026). ## Key facts | Fact | Value | |---|---| | Ticker (LSE) | SBIX | | ISIN | IE00BQ70R696 | | Category | Technology | | Type | ETF | | Provider | Invesco | | Tracks | NASDAQ / Biotechnology | | Income | Accumulating | | Ongoing charge | 0.40% a year (£40 per £10,000) | | Fund size | £273m | | Launched | 2014 | | Domicile | Ireland | ## Past returns (periods to 30/09/2026) After the fund's ongoing charges. "Income reinvested" is total return; "price only" leaves out income paid out. Real returns are after ONS CPIH inflation. | Window | Return | After CPIH inflation | Measured as | |---|---|---|---| | 1 year | +46.09% | +41.50% | income reinvested | | 3 years | +62.26% | +46.42% | income reinvested | | 5 years | +35.16% | +5.66% | income reinvested | Returns: TradingView (delayed data). Inflation: ONS CPIH, latest month published. ## Calendar-year returns Calendar-year returns of Invesco NASDAQ Biotech UCITS ETF in pounds (price, with income reinvested in the fund): 2026 to 30/09/2026 +25.9%. Returns of Invesco NASDAQ Biotech UCITS ETF in pounds (price, with income reinvested in the fund) over the 12 months to 30/09/2026: +53.3%. | Year | Return | After CPIH inflation | Measured as | |---|---|---|---| | 2026 to 30/09/2026 | +25.9% | +22.4% | Price | ## Risk metrics | Window | Volatility | Max drawdown | |---|---|---| | 1 year | 18.78% | -5.95% | ## Largest fall Volatility of Invesco NASDAQ Biotech UCITS ETF in pounds, annualised from weekly returns to 30/09/2026: 18.8% over 1 year. Largest fall in the price of Invesco NASDAQ Biotech UCITS ETF since August 2025, in pounds: −5.9% from 03/07/2026 to 31/07/2026. On 30/09/2026 the price of Invesco NASDAQ Biotech UCITS ETF was at its highest weekly close since August 2025, in pounds. ## Charges compared with similar funds Ongoing charge of Invesco NASDAQ Biotech UCITS ETF 0.40% a year, as of 01/10/2026: 74 of the 118 other technology funds charge more, 11 the same and 33 less (share classes counted once). ## Funds tracking the same index 3 funds track NASDAQ / Biotechnology, this one included and share classes counted once; their ongoing charges range from 0.35% to 0.40% a year (30/09/2026). | Fund | Ongoing charge | 1 year | 3 years | 5 years | |---|---|---|---|---| | Invesco NASDAQ Biotech UCITS ETF (this fund) | 0.40% | +46.1% | +62.3% | +35.2% | | iShares NASDAQ US Biotechnology UCITS ETF | 0.35% | +49.5% | +68.0% | +44.4% | | iShares NASDAQ US Biotechnology UCITS ETF | 0.35% | +50.0% | +68.0% | +45.9% | Returns are the data vendor’s, in pounds, income reinvested unless marked "(price)". ## Charges & eligibility - Ongoing charges figure (OCF): **0.40%** per year - ISA eligible: yes - SIPP eligible: yes ## Top holdings Largest positions (as of 30/09/2026): | Holding | Weight | |---|---| | Gilead Sciences | 8.16% | | Amgen | 7.85% | | Vertex Pharmaceuticals | 7.69% | | Moderna | 5.04% | | Regeneron Pharmaceuticals | 5.03% | | Revolution Medicines | 2.88% | | Illumina | 2.71% | | Biogen | 2.19% | | Alnylam Pharmaceuticals | 2.16% | | Roivant Sciences | 1.73% | ## Where it invests Shares of the whole fund. Bonds, cash and positions the source does not classify are shown as they come, not guessed. ### By sector As published by Invesco, as of 30/09/2026. | Sector | Weight | |---|---| | Information Technology | 34.4% | | Health Care | 15.0% | | Financials | 13.2% | | Consumer Discretionary | 12.9% | | Industrials | 9.1% | | Communication Services | 5.5% | | Materials | 3.2% | | Energy | 2.8% | | Other sectors | 3.9% | ### By country As published by Invesco, as of 30/09/2026. | Country | Weight | |---|---| | United States | 87.6% | | Switzerland | 5.6% | | South Korea | 1.3% | | Netherlands | 1.1% | | Mexico | 1.0% | | Brazil | 0.9% | | Sweden | 0.9% | | Israel | 0.4% | | Other countries | 1.1% | All 244 holdings: https://fundology.uk/fund/sbix/holdings --- We show information. We are not financial advisers, not authorised by the FCA, and never recommend specific investments. Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.